General Updates

September 28, 2026 BSE Limited, National Stock Exchange of India Limited, Floor 25, P. J. Towers Exchange Plaza, Bandra-Kurla Complex, Dalal Street, Fort Bandra (E), Mumbai - 400 001 Mumbai - 400051 Scrip Code: 530019 Symbol: JUBLPHARMA Sub.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 Dear Sirs, With reference to the SEBI Master Circular HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 6, 2026, attached is the specimen of the intimation sent today to those security holders whose final dividend for the financial year 2025-26 have been withheld due to non-submission of KYC documents. The above information will also be available on the website of the Company at www.jubilantpharmova.com. We request you to take the same on record. Thanking you, Yours faithfully, For Jubilant Pharmova Limited Naresh Kapoor Company Secretary Encl.: As above SPECIMEN LETTER JUBILANT PHARMOVA LIMITED (CIN: L24116UP1978PLC004624) Regd. Office: Bhartiagram, Gajraula, District Amroha - 244223, Uttar Pradesh, India Email: investors@jubl.com; Website: www.jubilantpharmova.com Phone: +91-5924-267437 Folio No. Date: Subject: Intimation regarding Non submission of KYC details in respect of physical shareholdings and withholding of final dividend payment for the financial year 2025-26 Ref: SEBI Master Circular No. HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 6, 2026 Dear Member, Pursuant to the SEBI Master Circular HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 6, 2026, read with Regulation 12 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, payment of dividend through any mode other than electronic mode is discontinued. Accordingly, shareholders holding securities in physical form are required to ensure that the requisite KYC particulars are updated, including PAN, postal address, email address, mobile number, bank account details and specimen signature, as applicable, are registered in their folios. As per the records of the Company/ Registrar & Share Transfer Agent (‘RTA”), the requisite KYC and/or bank account details in respect of your folio are incomplete or not updated. Consequently, the final dividend for the financial year 2025-26 payable in respect of your shareholding, as detailed below, has been withheld. The dividend shall be remitted through electronic mode only after the requisite KYC and bank account details are registered and successfully validated in the records of the Company/RTA, subject to applicable tax requirements. No. of equity shares held on record date i.e., on July 24, 2026 Dividend per share (INR) Gross dividend amount (INR) Tax deducted at source (INR) Net dividend amount (INR) Rate at which tax is deducted (%) Payment date Status of Payment Reason of withholding For the purpose of updation of KYC details against your folio, you are requested to furnish duly filled documents / details as mentioned below: a. Form ISR-1 for KYC update, along with self-attested supporting documents; and b. Form ISR-2 for banker attestation of signature along with original cancelled cheque with your name(s) printed thereon or self-attested copy of bank passbook/statement; c. Form SH-13 for updation of Nomination for the aforesaid folio; or d. Form ISR-3 for “Opt-out of the Nomination”. The aforesaid forms can be downloaded from the website of the Company https://www.jubilantpharmova.com/investors/investor-information/updation-of-kyc- details. Kindly send self-attested hard copies of the aforesaid documents to our RTA at Alankit Assignments Limited, 205-208, AnarKali Complex, Jhandewalan Extension, New Delhi -110 055, phone: +91 11 42541234, email: rta@alankit.com. We request you to treat this as our intimation regarding the withholding of Final Dividend for the financial year 2025-26 and updation of KYC details as mandated by SEBI. Thanking you, Yours faithfully For Jubilant Pharmova Limited Sd/- Naresh Kapoor Company Secretary Membership No. A11782